The Immunopathogenesis of Psoriasis

Dermatologic Clinics

Volumn 33, Issue 1, 2015, Pages 13-23

  Kim, Jaehwan ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Dendritic cells; Immunology; Immunopathogenesis; Keratinocyte; Psoriasis; T cells

Indexed keywords

ALEFACEPT; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 23P40; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALPHABETA T LYMPHOCYTE; BONE MARROW CELL; CELL MIGRATION; CELL TYPE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DERMATITIS; DISEASE MODEL; GAMMADELTAT LYMPHOCYTE; GENE ACTIVATION; GENE PRODUCT; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; KERATINOCYTE; LANGERHANS CELL; LYMPHOCYTE COUNT; MACROPHAGE MIGRATION; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PHENOTYPE; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; BIOLOGICAL MODEL; IMMUNOLOGY; MACROPHAGE; PATHOLOGY; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; INTERLEUKIN-17; KERATINOCYTES; KILLER CELLS, NATURAL; MACROPHAGES; MODELS, BIOLOGICAL; NEUTROPHILS; PSORIASIS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911495641     PISSN: 07338635     EISSN: 15580520     Source Type: Journal    
DOI: 10.1016/j.det.2014.09.002     Document Type: Review

References (90)

1. Lowes M.A., Suárez-Fariñas M., Krueger J.G. Immunology of psoriasis. Annu Rev Immunol 2014, 32:227-255.
2. Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu Rev Pathol 2012, 7:385-422.
3. Gottlieb S.L., Gilleaudeau P., Johnson R., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995, 1:442-447.
4. Valdimarsson H., Bake B.S., Jónsdótdr I., et al. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986, 7:256-259.
5. Abrams J.R., Lebwohl M.G., Guzzo C.A., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. JClin Invest 1999, 103:1243-1252.
6. Nograles K.E., Krueger J.G. Anti-cytokine therapies for psoriasis. Exp Cell Res 2011, 317:1293-1300.
7. Nestle F.O., Di Meglio P., Qin J.Z., et al. Skin immune sentinels in health and disease. Nat Rev Immunol 2009, 9:679-691.
8. Martin D.A., Towne J.E., Kricorian G., et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. JInvest Dermatol 2013, 133(1):17-26.
9. Kennedy-Crispin M., Billick E., Mitsui H., et al. Human keratinocytes' response to injury upregulates CCL20 and other genes linking innate and adaptive immunity. JInvest Dermatol 2012, 132:105-113.
10. Nograles K.E., Zaba L.C., Guttman-Yassky E., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008, 159:1092-1102.
11. Takai T. TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergol Int 2012, 61:3-17.
12. Eyerich S., Eyerich K., Pennino D., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. JClin Invest 2009, 119:3573-3585.
13. Murphy K. Janeway's immunobiology 2011, Garland Science, New York.
14. Streilein J.W. Skin-associated lymphoid tissues (SALT): origins and functions. JInvest Dermatol 1983, 80(Suppl):12s-16s.
15. Egawa G., Kabashima K. Skin as a peripheral lymphoid organ: revisiting the concept of skin-associated lymphoid tissues. JInvest Dermatol 2011, 131:2178-2185.
16. Di Meglio P., Perera G.K., Nestle F.O. The multitasking organ: recent insights into skin immune function. Immunity 2011, 35:857-869.
17. Bos J.D., De Rie M.A. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999, 20:40-46.
18. Ferenczi K., Burack L., Pope M., et al. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. JAutoimmun 2000, 14:63-78.
19. Bos J.D., Hulsebosch H.J., Krieg S.R., et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983, 275:181-189.
20. Cai Y., Fleming C., Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 2012, 9:302-309.
21. Spits H., Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012, 30:647-675.
22. Villanova F., Flutter B., Tosi I., et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. JInvest Dermatol 2014, 134:984-991.
23. Lowes M.A., Russell C.B., Martin D.A., et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013, 34:174-181.
24. Cai Y., Shen X., Ding C., et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011, 35:596-610.
25. Laggner U., Di Meglio P., Perera G.K., et al. Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis. JImmunol 2011, 187:2783-2793.
26. Goodman W.A., Cooper K.D., McCormick T.S. Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol 2012, 32:65-79.
27. Palmer M.T., Weaver C.T. Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol 2010, 11:36-40.
28. Buckner J.H. Mechanisms of impaired regulation byCD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010, 10:849-859.
29. Sugiyama H., Gyulai R., Toichi E., et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. JImmunol 2005, 174:164-173.
30. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. JInvest Dermatol 2009, 129:79-88.
31. Nestle F.O., Zheng X.G., Thompson C.B., et al. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. JImmunol 1993, 151:6535-6545.
32. Cerio R., Griffiths C.E., Cooper K.D., et al. Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 1989, 121:421-431.
33. Zaba L.C., Fuentes-Duculan J., Steinman R.M., et al. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. JClin Invest 2007, 117:2517-2525.
34. Dzionek A., Fuchs A., Schmidt P., et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. JImmunol 2000, 165:6037-6046.
35. Kennedy Crispin M., Fuentes-Duculan J., Gulati N., et al. Gene profiling of narrowband UVB-induced skin injury defines cellular and molecular innate immune responses. JInvest Dermatol 2013, 133:692-701.
36. Hyder L.A., Gonzalez J., Harden J.L., et al. TREM-1 as a potential therapeutic target in psoriasis. JInvest Dermatol 2013, 133:1742-1751.
37. Johnson-Huang L.M., McNutt N.S., Krueger J.G., et al. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. JClin Immunol 2009, 29:247-256.
38. Johnson-Huang L.M., Lowes M.A., Krueger J.G. Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech 2012, 5:423-433.
39. Hansel A., Gunther C., Ingwersen J., et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. JAllergy Clin Immunol 2011, 127:787-794.e1-9.
40. Cumberbatch M., Singh M., Dearman R.J., et al. Impaired Langerhans cell migration in psoriasis. JExp Med 2006, 203:953-960.
41. Shaw F.L., Cumberbatch M., Kleyn C.E., et al. Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. JInvest Dermatol 2010, 130:1940-1942.
42. Shaw F.L., Mellody K.T., Ogden S., et al. Treatment-related restoration of Langerhans cell migration in psoriasis. JInvest Dermatol 2014, 134:268-271.
43. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
44. Fabriek B.O., Dijkstra C.D., van den Berg T.K. The macrophage scavenger receptor CD163. Immunobiology 2005, 210:153-160.
45. Fuentes-Duculan J., Suarez-Farinas M., Zaba L.C., et al. Asubpopulation of CD163-positive macrophages is classically activated in psoriasis. JInvest Dermatol 2010, 130:2412-2422.
46. Wang F., Lee E., Lowes M.A., et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. JInvest Dermatol 2006, 126:1590-1599.
47. Zaba L.C., Cardinale I., Gilleaudeau P., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. JExp Med 2007, 204:3183-3194.
48. Knight J.S., Carmona-Rivera C., Kaplan M.J. Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Front Immunol 2012, 3:380.
49. Aubert P., Suarez-Farinas M., Mitsui H., et al. Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1beta. PLoS One 2012, 7:e49408.
50. Lin A.M., Rubin C.J., Khandpur R., et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. JImmunol 2011, 187:490-500.
51. Dunphy S., Gardiner C.M. NK cells and psoriasis. JBiomed Biotechnol 2011, 2011:248317.
52. Simoni Y., Diana J., Ghazarian L., et al. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?. Clin Exp Immunol 2013, 171:8-19.
53. Bonish B., Jullien D., Dutronc Y., et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. JImmunol 2000, 165:4076-4085.
54. van der Fits L., Mourits S., Voerman J.S., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. JImmunol 2009, 182:5836-5845.
55. Ganguly D., Chamilos G., Lande R., et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. JExp Med 2009, 206:1983-1994.
56. Gilliet M., Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol 2008, 20:401-407.
57. Lande R., Gregorio J., Facchinetti V., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
58. Kumar V., Sharma A. Neutrophils: Cinderella of innate immune system. Int Immunopharmacol 2010, 10:1325-1334.
59. Nestle F.O., Turka L.A., Nickoloff B.J. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. JClin Invest 1994, 94:202-209.
60. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. JAllergy Clin Immunol 2010, 125:1261-1268.e9.
61. Austin L.M., Ozawa M., Kikuchi T., et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. JInvest Dermatol 1999, 113:752-759.
62. Lowes M.A., Kikuchi T., Fuentes-Duculan J., et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. JInvest Dermatol 2008, 128:1207-1211.
63. Suárez-Fariñas M., Lowes M.A., Zaba L.C., et al. Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One 2010, 5:e10247.
64. Krueger J.G., Fretzin S., Suarez-Farinas M., et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. JAllergy Clin Immunol 2012, 130:145-154.e9.
65. Papp K.A., Leonardi C., Menter A., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. NEngl J Med 2012, 366:1181-1189.
66. Papp K.A., Reid C., Foley P., et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. JInvest Dermatol 2012, 132:2466-2469.
67. Leonardi C., Matheson R., Zachariae C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. NEngl J Med 2012, 366:1190-1199.
68. Chiricozzi A., Nograles K.E., Johnson-Huang L.M., et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One 2014, 9:e90284.
69. Datta S., Novotny M., Pavicic P.G., et al. IL-17 regulates CXCL1 mRNA stability via an AUUUA/tristetraprolin-independent sequence. JImmunol 2010, 184:1484-1491.
70. Chiricozzi A., Guttman-Yassky E., Suarez-Farinas M., et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. JInvest Dermatol 2011, 131:677-687.
71. Ruddy M.J., Wong G.C., Liu X.K., et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. JBiol Chem 2004, 279:2559-2567.
72. Shen F., Hu Z., Goswami J., et al. Identification of common transcriptional regulatory elements in interleukin-17 target genes. JBiol Chem 2006, 281:24138-24148.
73. Lowes M.A., Chamian F., Abello M.V., et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005, 102:19057-19062.
74. Zaba L.C., Krueger J.G., Lowes M.A. Resident and "inflammatory" dendritic cells in human skin. JInvest Dermatol 2009, 129:302-308.
75. Summers deLuca L., Gommerman J.L. Fine-tuning of dendritic cell biology by the TNF superfamily. Nat Rev Immunol 2012, 12:339-351.
76. Lew W., Bowcock A.M., Krueger J.G. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "type 1" inflammatory gene expression. Trends Immunol 2004, 25:295-305.
77. Johnson-Huang L.M., Suarez-Farinas M., Pierson K.C., et al. Asingle intradermal injection of IFN-gamma induces an inflammatory state in both non-lesional psoriatic and healthy skin. JInvest Dermatol 2012, 132:1177-1187.
78. Sofen H., Smith S., Matheson R.T., et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. JAllergy Clin Immunol 2014, 133:1032-1040.
79. Harden J., Johnson-Huang L.M., Chamian M.F., et al. Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis. JAllergy Clin Immunol 2014, [Epub ahead of print].
80. Kryczek I., Bruce A.T., Gudjonsson J.E., et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. JImmunol 2008, 181:4733-4741.
81. Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. JClin Invest 2007, 117:871-873.
82. Cua D.J., Sherlock J., Chen Y., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
83. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. JClin Invest 2002, 110:493-497.
84. Banno T., Gazel A., Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. JBiol Chem 2004, 279:32633-32642.
85. Wolk K., Kunz S., Witte E., et al. IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241-254.
86. Harper E.G., Guo C., Rizzo H., et al. Th17 cytokines stimulate CCL20 expression in keratinocytes invitro and invivo: implications for psoriasis pathogenesis. JInvest Dermatol 2009, 129:2175-2183.
87. Blumenberg M. SKINOMICS: transcriptional profiling in dermatology and skin biology. Curr Genomics 2012, 13:363-368.
88. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
89. Kim T.G., Jee H., Fuentes-Duculan J., et al. Dermal clusters of mature dendritic cells and T cells are associatedwith the CCL20/CCR6 chemokine system in chronic psoriasis. JInvest Dermatol 2014, 134:1462-1465.
90. Mitsui H., Suarez-Farinas M., Belkin D.A., et al. Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. JInvest Dermatol 2012, 132:1615-1626.